[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100417877":3},{"organization":4,"armGroups":7,"interventions":16,"overallOfficials":22,"centralContacts":26,"locations":32,"responsibleParty":49,"collaborators":51,"id":55,"slug":56,"hasResults":57,"nctId":58,"briefTitle":59,"officialTitle":59,"acronym":10,"eligibilityCriteria":60,"healthyVolunteers":61,"sex":62,"minAge":63,"maxAge":64,"enrollmentInfo":65,"targetDuration":10,"studyType":68,"phases":10,"briefSummary":69,"conditions":70,"keywords":10,"overallStatus":35,"whyStopped":10,"lastUpdateSubmitDate":72,"lastUpdatePostDateStruct":73,"startDateStruct":76,"completionDateStruct":78,"leadSponsor":80,"locationsCount":81},{"fullName":5,"class":6},"Yale University","OTHER",[8,13],{"label":9,"type":10,"description":10,"interventionNames":11},"Cocaine Use Disorder",null,[12],"Radiation: 11C-UCB-J",{"label":14,"type":10,"description":10,"interventionNames":15},"Healthy Control",[12],[17],{"type":18,"name":19,"description":20,"armGroupLabels":21,"otherNames":10},"RADIATION","11C-UCB-J","11C-UCB-J PET scan",[9,14],[23],{"name":24,"affiliation":5,"role":25},"Gustavo Angarita, MD","PRINCIPAL_INVESTIGATOR",[27],{"name":28,"role":29,"phone":30,"phoneExt":10,"email":31},"Marcella Mignosa, MD","CONTACT","203 974 7557","marcella.mignosa@yale.edu",[33],{"facility":34,"status":35,"city":36,"state":37,"zip":38,"country":39,"countryCode":40,"cosmosGeoPoint":41,"geoPoint":46,"contacts":47},"Connecticut Mental Health Center","RECRUITING","New Haven","Connecticut","06519","United States","US",{"type":42,"coordinates":43},"Point",[44,45],-72.92816,41.30815,{"lat":45,"lon":44},[48],{"name":24,"role":29,"phone":10,"phoneExt":10,"email":10},{"type":50,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR",[52],{"name":53,"class":54},"National Institute on Drug Abuse (NIDA)","NIH","100417877","aberrant-synaptic-plasticity-in-cocaine-use-disorder-a-11c-ucb-j-pet-study-100417877",false,"NCT04721418","Aberrant Synaptic Plasticity in Cocaine Use Disorder: A 11C-UCB-J PET Study","Inclusion Criteria:\n\n* Age 21-60 years\n* Physically healthy by medical history, physical, neurological, ECG and laboratory examinations\n* For females, a negative serum pregnancy test\n* For CUD: DSM-5 criteria for Cocaine Use Disorder and positive urine toxicology showing recent use\n* For HC: Negative urine toxicology\n\nExclusion Criteria:\n\n* DSM-5 criteria for other substance use disorders (e.g., alcohol, opiates, sedative hypnotics), except for nicotine\n* A primary DSM-5 Axis I major psychiatric disorder (e.g., schizophrenia, bipolar disorder, major depression, etc.) as determined by the Structured Clinical Interview for DSM-5 (SCID-5)\n* A history of significant and\u002For uncontrolled medical or neurological illness\n* Current use of psychotropic and\u002For potentially psychoactive prescription medications\n* Medical contraindications to MRI procedure",true,"ALL","21 Years","60 Years",{"count":66,"type":67},80,"ESTIMATED","OBSERVATIONAL","The purpose of this research study is to measure synaptic density in the brain comparing individuals with cocaine use disorder to healthy controls.",[9,71],"Healthy Controls","2025-09-09",{"date":74,"type":75},"2025-09-11","ACTUAL",{"date":77,"type":75},"2021-07-20",{"date":79,"type":67},"2026-06",{"name":5,"class":6},1]